This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.
The drug VAXELIS contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
IRH51QN26H - CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)
|
2
|
UNII
K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)
|
3
|
UNII
F4TN0IPY37 - BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED)
|
4
|
UNII
8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)
|
5
|
UNII
63GD90PP8X - BORDETELLA PERTUSSIS PERTACTIN ANTIGEN
|
6
|
UNII
1O0600285A - BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGEN
|
7
|
UNII
0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)
|
8
|
UNII
23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)
|
9
|
UNII
459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)
|
10
|
UNII
XL4HLC6JH6 - HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN
|
|
Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. |
|
11
|
UNII
LUY6P8763W - HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER MEMBRANE PROTEIN CONJUGATE ANTIGEN
|
|
Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J07CA09 | Diphtheria-Haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B | J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1711347, 1711358, 1711369, 1849552 |
| ES | Centro de información online de medicamentos de la AEMPS | 1151079004 |
| FR | Base de données publique des médicaments | 69688620 |
| GB | Medicines & Healthcare Products Regulatory Agency | 393672 |
| IT | Agenzia del Farmaco | 044721013, 044721025, 044721037, 044721049, 044721052, 044721064, 044721076, 044721088 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1079673, 1079674, 1079675, 1079676, 1079677, 1079678, 1079680, 1089619 |
| NL | Z-Index G-Standaard, PRK | 196541 |
| PL | Rejestru Produktów Leczniczych | 100366850 |
| US | FDA, National Drug Code | 63361-243 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.